The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors

World Journal of Surgical Oncology

Marian Brocki¹  Sławomir Jabłoński¹  Ewa Malecka-Panas²  Renata Talar -Wojnarowska²  Łukasz Piskorz¹  Jacek Śmigielski¹ 

[1] Department of Thoracic, General and Oncological Surgery, Medical University, 113 Zeromskiego Street, 90-549 Lodz, Poland;Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland

关键词: TIMP-2;    TIMP-1;    MMP-9;    MMP-2;    Pancreatic tumor;    Pancreatic cancer;   

Others  :  823829
DOI  :  10.1186/1477-7819-11-137

 received in 2012-10-22, accepted in 2013-06-01,  发布年份 2013

【 摘 要 】

Background

The aim of the study was to evaluate the concentration of proteolytic enzymes, MMP-2 and MMP-9, and their tissue inhibitors, TIMP-1 and TIMP-2, in the blood of patients with benign and malignant pancreatic tumors.

Methods

MMP-2, MMP-9, TIMP-1, and TIMP-2 were evaluated in the patients with benign and malignant pancreatic tumors before surgery and in the 30-day follow-up. The study covered 134 patients aged 54 to 76 years, who were divided into groups by TNM staging.

Results

Before the operation, the highest mean concentration of MMP-2 was found in patients with unresectable cancer, whereas the highest level of MMP-9 was in patients with resectable cancer. The highest level of TIMP-1 was noted in patients with inflammatory tumors. In 1 month following the operation, the highest level of MMP-2 was also in patients with unresectable cancer and the highest level of TIMP-2 in patients with inflammatory tumors.

Conclusions

The evaluation of the level of the studied cytokines in the pancreatic tumor patients can be diagnostically significant in the differentiation of benign and malignant changes. The changes in the levels of the studied enzymes and their inhibitors can have a prognostic value in the clinical severity of pancreatic cancer.

【 授权许可】

   
2013 Śmigielski et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002, 236:355-366.
• [2]Stadnik H, Brzuzgo K, Szmeja J, Janicka-Jedyńska M, Majewski P, Drews M: Assesment of diagnostic and prognostic value of transduodenal fine need biopsy in patients with tumors in pancreatic head in material of department of general, oncological and endocrinological burgery, Medical University in Poznan. Pol Przeg Chir 2010, 82:1049-1056.
• [3]Palade GE, Simoniescu M, Simionescu N: Structural aspects of the permeability of the microvascular endothelium. Acta Physiol Scand 1979, 463:11-32.
• [4]Folkman J: Clinical application of research on angiogenesis. N Engl J Med 1995, 333:1757-1763.
• [5]O’Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB, Schwartz SM: Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994, 145:883-894.
• [6]Colville Nash PR, Scott DL: Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992, 51:919-925.
• [7]Sharp PS: The role of growth factors in the development of diabetic retinopathy. Metabolism 1995, 44:72-75.
• [8]Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ: Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994, 144:820-828.
• [9]Folkman J: What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 1990, 82:4-6.
• [10]Ray JM, Stetler-Stevenson WG: The role of matrix metalloproteinases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994, 7:2062-2072.
• [11]Śmigielski J, Brocki M, Kuzdak K, Kołomecki K: Serum MMP-2 and TIMP-2 in patients with inguinal hernias. Eur J Clin Invest 2011, 6:584-588.
• [12]Śmigielski J, Kołomecki K, Ziemniak P, Drozda R, Amsolik M, Kuzdak K: Degradation of collagen by metalloproteinase 2 in patients with abdominal hernias. Eur Surg Res 2009, 42:118-121.
• [13]Talbot DC, Brown PD: Experimental and clinical studies on the use of matrix metalloproteinase inhibitor for the treatment of cancer. Eur J Cancer 1996, 32A:2528-2533.
• [14]Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, Jurkowska G, Szmitkowski M: Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009, 38:613-618.
• [15]Giannopoulos G, Pavlakis K, Parasi A, Kavatzas N, Tiniakos D, Karakosta A, Tzanakis N, Peros G: The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res 2008, 28:1875-1881.
• [16]Jamieson NB, Carter CR, McKay CJ, Oien KA: Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res 2011, 17:3316-3331.
• [17]Fitzmaurice C, Seiler CM, Büchler MW, Diener MK: Survival, mortality and quality of life after pylorus-preserving or classical Whipple operation. A systematic review with meta-analysis. Chirurg 2010, 81:454-471.
• [18]Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, Büchler MW, Neoptolemos JP, Pancreatic Cancer Meta-Analysis Group: Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008, 143:75-83.
• [19]Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S, Kokudo N, Fukayama M: Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem 2011, 59:942-952.
• [20]Bausch D, Thomas S, Mino-Kenudson M, Fernández-del CC, Bauer TW, Williams M, Warshaw AL, Thayer SP, Kelly KA: Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res 2011, 17:302-309.
• [21]Yu J, Ohuchida K, Mizumoto K, Ishikawa N, Ogura Y, Yamada D, Egami T, Fujita H, Ohashi S, Nagai E, Tanaka M: Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroenterol 2006, 12:3878-3882.
• [22]Kumagai Y, Toi M, Kawada K, Kawano T: Angiogenesis in superficial esophageal squamous cell carcinoma: magnifying endoscopic observation and molecular analysis. Dig Endosc 2010, 22:259-267.
• [23]Wu FP, Hoekman K, Sietses C, von Blomberg BM, Meijer S, Bonjer HJ, Cuesta MA: Systemic and peritoneal angiogenic response after laparoscopic or conventional colon resection in cancer patients: a prospective, randomized trial. Dis Colon Rectum 2004, 47:1670-1674.
• [24]Nalwoga H, Arnes JB, Stefansson IM, Wabinga H, Foulkes WD, Akslen LA: Vascular proliferation is increased in basal-like breast cancer. Breast Cancer Res Treat 2011, 130:1063-1071.
• [25]Li S, Ibaragi S, Hu GF: Angiogenin as a molecular target for the treatment of prostate cancer. Curr Cancer Ther Rev 2011, 7:83-90.
• [26]Kopczyńska E, Makarewicz R, Tyrakowski R: The role of angiopoietins 1 and 2 in the regulation of tumor angiogenesis. Contemp Oncol 2007, 7:350-354.
• [27]Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K, Imai K: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001, 19:1118-1127.
• [28]Morán A, Iniesta P, García-Aranda C, De Juan C, Díaz-López A, Sánchez-Pernaute A, Torres AJ, Díaz-Rubio E, Balibrea JL, Benito M: Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep 2005, 13:115-120.
• [29]Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Noguchi Y: Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer. Cancer Lett 2000, 151:81-86.
• [30]Iniesta P, Morán A, De Juan C, Gómez A, Hernando F, García-Aranda C, Frías C, Díaz-López A, Rodríguez-Jiménez FJ, Balibrea JL, Benito M: Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep 2007, 17:217-223.